Epicrispr Biotechnologies
South San Francisco, California, United States · Biotechnology, Genetics, Health Care · 38 employees
Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases. Their lead program, EPI-321, is a first-in-class disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). The company aims to advance innovative treatments that address the underlying causes of genetic disorders. With recent funding, Epicrispr is ent
Funding history
- Series series b — $68.0M — Mar 2025
Recent signals
- May 05, 2026: Epicrispr Biotechnologies and Forge Biologics Announce Strategic Partnership for AAV Development and Manufacturing of EPI-321.
- Apr 23, 2025: Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
- Mar 27, 2025: Raised $68.0M in Series series b
See plans & pricing → Track Epicrispr Biotechnologies’s funding, hiring, and signals — with verified contacts — on Fundz.